Aspects of the present invention provide stable liquid ready-to-use injectable formulation of bortezomib or pharmaceutically acceptable salts thereof. Another aspect of the present invention provides processes for preparation of such stable liquid ready-to-use injectable formulation of bortezomib and methods of using such formulations for treating various types of cancers in mammals.